Navigation Links
Upcoming meeting will explore new technologies for glaucoma clinical drug trials

Rockville, MD The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.

Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria i.e., a vision field test as the primary functional outcome measure.

However, new technologies that assess abnormalities and changes in the optic nerve structure and its function offer vision researchers alternative pathways to better diagnose and treat glaucoma.

This symposium will focus on new outcome measures appropriate for evaluation of glaucoma therapies. The aim is to encourage the development of new glaucoma therapies, facilitate their evaluation and ultimately benefit patients.

Attendees will include:

  • Clinical researchers/basic scientists
  • Clinical trialists
  • Pharmaceutical company representatives
  • Legal/advocacy firms
  • Associations
  • Biotech companies

Registrants will be able to submit questions/comments in advance through a link on their registration confirmation notice.

Glaucoma facts

Glaucoma a potentially blinding but treatable group of diseases affects 2.2 million Americans age 40 and older, resulting in direct medical costs of $2.86 billion annually.

  • Glaucoma robs individuals of peripheral and eventually central vision.
  • Glaucoma is a complex group of neurodegenerative diseases that arises from progressive damage to the optic nerve and retinal ganglion cells and their axons.
  • It is one of the four major aging eye diseases, alongside age-related macular degeneration, diabetic retinopathy and cataracts.
  • About 50 percent of sufferers are unaware they have the disease.
  • Glaucoma disproportionately affects minority populations: It is three times more common in African Americans than in whites and is the leading cause of irreversible vision loss in African Americans and Hispanics.
  • There is a large public health burden from glaucoma due to decreased productivity, reduced independence and diminished quality of life.


Contact: Lancey Cowan
Association for Research in Vision and Ophthalmology

Related medicine news :

1. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
2. Align Technology Executives to Present at Upcoming Financial Conferences
3. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
4. The Advisory Board Company to Present at Upcoming Conferences
5. Coherent Announces Director Slate for Upcoming Annual Meeting
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. LCA-Vision Announces Upcoming Investment Community Events
8. WellPoint Announces Appearance at Upcoming Conference
9. Thought Leaders in Morbid Obesity Treatment Convene at Upcoming Surgical Conference
10. GSI to Present at Upcoming Investor Growth Conferences
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: